Clinical Studies Section of Labeling for Human Prescription Drug and Biological Products — Content and Format: Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
January 24, 2006
January 31, 2025
8675c759-b657-4818-9bed-199de1148828
Related Documents
Adverse Reactions Section of Labeling for Human Prescription Drug and Biological Products — Content and Format
Guidance DocumentJanuary 24, 2006Center for Drug Evaluation and Research
IND Exemptions for Studies of Lawfully Marketed Drug or Biological Products for the Treatment of Cancer: Guidance for Industry
Guidance DocumentJanuary 15, 2004Center for Drug Evaluation and Research
S8 Immunotoxicity Studies for Human Pharmaceuticals
Guidance DocumentApril 12, 2006Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox